State Street Corp Has $1.60 Million Holdings in Eliem Therapeutics, Inc. (NASDAQ:ELYM)

State Street Corp lifted its stake in Eliem Therapeutics, Inc. (NASDAQ:ELYM) by 433.9% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 315,036 shares of the company’s stock after acquiring an additional 256,029 shares during the period. State Street Corp owned 1.06% of Eliem Therapeutics worth $1,604,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Point72 Asset Management L.P. acquired a new position in shares of Eliem Therapeutics during the third quarter worth approximately $3,008,000. Parkman Healthcare Partners LLC acquired a new position in Eliem Therapeutics in the 3rd quarter valued at approximately $1,419,000. Ikarian Capital LLC lifted its position in shares of Eliem Therapeutics by 75.1% in the 3rd quarter. Ikarian Capital LLC now owns 175,100 shares of the company’s stock worth $891,000 after acquiring an additional 75,100 shares during the period. Janus Henderson Group PLC grew its holdings in shares of Eliem Therapeutics by 10.8% during the 3rd quarter. Janus Henderson Group PLC now owns 3,606,495 shares of the company’s stock worth $18,303,000 after purchasing an additional 352,507 shares in the last quarter. Finally, Ally Bridge Group NY LLC increased its position in shares of Eliem Therapeutics by 145.9% during the third quarter. Ally Bridge Group NY LLC now owns 1,229,292 shares of the company’s stock valued at $6,257,000 after purchasing an additional 729,292 shares during the period. 69.76% of the stock is currently owned by institutional investors and hedge funds.

Eliem Therapeutics Stock Down 2.7 %

NASDAQ ELYM opened at $1.80 on Thursday. The stock has a market cap of $53.55 million, a P/E ratio of -3.40 and a beta of -0.39. Eliem Therapeutics, Inc. has a twelve month low of $2.35 and a twelve month high of $11.55. The company’s 50-day simple moving average is $3.17 and its 200 day simple moving average is $5.51.

About Eliem Therapeutics

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.